dipeptidyl peptidase-4 (DPP-4) inhibitor – CRI Report https://www.cri-report.com market research vender! Thu, 02 Dec 2021 07:18:45 +0000 en-US hourly 1 https://www.cri-report.com/wp-content/uploads/2021/01/cropped-shcrilogo-c.jpg dipeptidyl peptidase-4 (DPP-4) inhibitor – CRI Report https://www.cri-report.com 32 32 Investigation Report on China’s Sitagliptin Market 2021-2025 https://www.cri-report.com/investigation-report-on-chinas-sitagliptin-market-2021-2025/ Fri, 04 Jun 2021 06:22:38 +0000 https://www.cri-report.com/?post_type=product&p=11716 In 2020, due to the impact of the COVID-19 epidemic, the growth rate of Sitagliptin sales fell, but the sale value of Sitagliptin reached CNY389.69 million.

The post Investigation Report on China’s Sitagliptin Market 2021-2025 first appeared on CRI Report.

]]> Sitagliptin is the world’s first listed oral dipeptidyl peptidase-4 (DPP-4) inhibitor, developed by Merck Sharp & Dohme Ltd (JANUVIA). It was approved by the U.S. FDA in October 2006 to be used as a single drug or combination with metformin and thiazolidinedione drugs to improve blood sugar control in type II diabetes. In April 2007, a combination of Sitagliptin and metformin was approved in the United States; in September 2009, the CFDA approved Sitagliptin to enter the Chinese market; in July 2012, the CFDA approved the registration of its combination in China. By 2020, Merck Sharp & Dohme Ltd is the only manufacturers in the Sitagliptin market in China.

According to CRI’s market research, Sitagliptin’s sales in the Chinese market have increased year by year. Sitagliptin was included in the medical insurance reimbursement catalog in 2017, so the sales value of China’s Sitagliptin growth in 2018 was the most obvious, rising from CNY116.98 million in 2017 to CNY233.37 million in 2018, with an annual growth rate of 99.50%. In 2020, due to the impact of the COVID-19 epidemic, the growth rate of Sitagliptin sales fell, but the sale value of Sitagliptin reached CNY389.69 million. The CAGR of Sitagliptin’s sales value in the Chinese market from 2016 to 2020 is 47.44%.

CRI expects that its sales will continue to grow from 2021 to 2025 as the effective alleviation of the COVID-19 epidemic. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. successfully won the first domestic imitation of Sitagliptin after the approval in 2020 and became the fourth domestically-made DPP-4 inhibitor drug. The patent of Sitagliptin will expire in 2022. In the future, its manufacturers will gradually increase, the market will continue to expand, and prices will have a downward trend, which will lead to an increase in Sitagliptin sales and sales volume. Compared with traditional hypoglycemic drugs, sitagliptin does not increase the risk of hypoglycemia and affects weight Neutrality, good cardiovascular safety, and other advantages. Based on these advantages, Sitagliptin ranks first in the DPP-4 inhibitor market. In addition, the huge patient population. The huge patient population will enable the Sitagliptin market to continue to expand. Therefore, Sitagliptin sales will continue to grow from 2021 to 2025 as the market expands.

Topics Covered:
-The impact of COVID-19 on China’s Sitagliptin market
– Sales value of China’s Sitagliptin 2016-2020
– Competitive landscape of China’s Sitagliptin market
– Prices of Sitagliptin in China
– Prices of Sitagliptin in China by regions and manufacturers
– Analysis of factors affecting the development of China’s Sitagliptin market
– Prospect of China’s Sitagliptin market from 2021 to 2025

The post Investigation Report on China’s Sitagliptin Market 2021-2025 first appeared on CRI Report.

]]>